Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

<div>Mean ± standard deviation etravirine plasma concentration-time curves after administration of etravirine 200 mg bid for two weeks in combination with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd and one NRTI. ATV/r: atazanavir/ritonavir; bid: twice daily; ETR: etravirine; NRTI: nucleoside reverse transcriptase inhibitor; qd: once daily.</div>

AIDS Research and Treatment

fig4

Figure 4

Figure 4: Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients 

Figure 4 | Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients 